🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats Aaron Anselmo on another NIH NOA, this time for a diversity supplement for BBSP @ UNC Microbiology and Immunology grad student Jilarie Santos Santiago. Terrific news for such a fantastic student!

I got a flu shot. Protects me. Protects you from me. Please get one, too!

Whenever my husband’s students mistakenly address him as Dr. Pomeroy, he corrects them saying “Dr. Pomeroy is my wife” #WomenInSTEM

Couldn't have said it better myself!

Thank you UNC TIBBS for hosting an ornament decorating party! Definitely brought some joy during a hard year. #TIBBSholidaze

I'm so excited to share the primary article from my graduate work, published today in Science Signaling! I am so proud of this project and thankful for all of my coauthors including Matthew Peña and Beverly Errede. @CompMedUNC UNC Biochemistry and Biophysics department UNC Pharmacology UNC School of Medicine stke.sciencemag.org/content/14/670…

So proud of our postdoc Dr. Amy Pomeroy for creating a model that can accurately predict clinical trial outcomes!

2 papers out! 1) Across many cancers, the clinical efficacy of combination immunotherapies is predictable from efficacy of their ingredients clincancerres.aacrjournals.org/content/28/2/3… 2) Review - what does this mean for precision oncology? cancerdiscovery.aacrjournals.org/content/early/… 1/n

I am so excited to share our review of drug independence and its role in curative cancer combination therapy just published #OpenAccess in Trends in Cancer. cell.com/trends/cancer/… #MathOnc #CompMed #SysBio UNC Pharmacology Adam C Palmer UNC School of Medicine UNC-Chapel Hill UNC Lineberger (1/8)

Thrilled (and flattered) to read this preview by one of my scientific heroes and leader in the field of drug #combinationtherapy Adam C Palmer @SarahCooperUNC

So proud of Haeun (Hannah) Hwangbo for giving a great talk on clinical drug additivity at #SACB2022!

@SarahCooperUNC was phenomenal at #SACB2022 poster session today!!!

#SACB2022 has been a great meeting with exciting research and fun people in a beautiful location. It's been a pleasure serving on the organizing committee over the last 3+ years

I hope we are moving away from “maximum tolerated dose” in oncology. #MedTwitter Of the studies I’ve led, the one I am most proud of is the trial that showed that LOWER dose of steroids led to better survival & lower toxicity. The Lancet Oncology #Myeloma thelancet.com/journals/lanon…

New paper: Most approved drug combinations for advanced cancer (1995-2020) have predictable clinical efficacy, because they have additive effect on Progression-Free Survival times. In Nature Cancer at rdcu.be/drhs0 by Haeun (Hannah) Hwangbo Sarah Patterson Deborah Plana, MD, PhD 1/6

I remember a long-ago FDA Oncology meeting with a small company developing an MDS drug. The company was convinced their drug was synergistic with HMAs & kept saying “we’re 2+2=5.” Finally an FDA official said they were perfectly happy for 2+2 to equal 4, if 4 was safe patients.

You don’t need ‘1+1 makes 3’ if you can have ‘5+5 makes 10’ - Adam C Palmer Nature Cancer Sarah Patterson Deborah Plana, MD, PhD Anthony Letai MD PhD David Steensma, MD oncodaily.com/21728.html #Cancer #FDAOncology #HypomethylatingAgents #HMAs #NatureCancer #OncoDaily #Oncology